Potentia Pharmaceuticals Inc.

Formerly started as an early stage nanotechnology company, Potentia Pharmaceuticals Inc. is now focused on developing novel therapeutics for macular degeneration--a disease that affects nearly 20 million people worldwide and that, until only three years ago, had little to no treatment.